Stay updated with breaking news from Nasdaq mltx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) is one of 1,001 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare MoonLake Immunotherapeutics to related businesses based on the strength of its analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk. Insider & Institutional Ownership 76.1% of […] ....
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating)’s stock price fell 3% during trading on Monday . The company traded as low as $26.71 and last traded at $26.73. 324,149 shares traded hands during mid-day trading, an increase of 29% from the average session volume of 251,680 shares. The stock had previously closed at $27.55. Analyst Upgrades […] ....
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $29.59 and last traded at $28.84, with a volume of 95815 shares traded. The stock had previously closed at $28.24. Analyst Ratings Changes Several research firms have recently weighed in […] ....
Guggenheim began coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) in a report issued on Monday morning, The Fly reports. The brokerage issued a buy rating on the stock. A number of other equities analysts have also recently commented on the company. Wedbush started coverage on MoonLake Immunotherapeutics in a report on Wednesday, […] ....
Guggenheim initiated coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) in a research report released on Monday, The Fly reports. The firm issued a buy rating on the stock. MLTX has been the topic of several other reports. Bryan, Garnier & Co started coverage on shares of MoonLake Immunotherapeutics in a research report […] ....